Fig. 2From: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsKaplan Meier analyses for progression free survival (PFS) according to categorical CTC-counts (<5 vs. ≥5) at baseline (q0) and after one (q1) and 4 (q4) cycles of docetaxelBack to article page